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Abstract: Aim: We aimed to evaluate the sensitivity of 18F-Flourodeoxyglucose (18F-FDG) positron emission 
tomography/computed tomography (PET/CT) in the detection of pelvic and paraaortic lymph node metastases of uterine 
cervical cancer.  
Material and Method: 32 female patients (mean age: 56.1±12.6) who underwent 18F-FDG PET/CT for preoperative 
staging of uterine cervical cancer between April 2009 and October 2013 were included to the study. Ethical committee 
approval was taken from Ankara University Medical Faculty Ethics Committee. All the patients had been performed 
trans-vaginal examination and diagnosed as uterine cervical cancer before 18F-FDG PET/CT. 18F-FDG PET/CT 
findings were compared with histopathological examination results. Sensitivity, specificity and accuracy of pelvic MRI 
and 18F-FDG PET/CT were calculated in the detection of pelvic and paraaortic lymph node metastases.  
Results: 18F-FDG uptake was seen in primary cervical lesions of all the patients. Mean SUV max of primary cervical 
lesions was calculated as 13.6±6.6 (range: 6.7-25). In 16 (50%) patients, 18F-FDG uptake was not seen in pelvic and 
paraaortic lymph nodes. In the remaining patients, 18F-FDG uptake was detected in pelvic nodes in all the patients 
(50%) and in paraaortic nodes in 6 (18%) patients. Mean SUV max of pelvic lymph nodes were calculated as 8.4±5.2 
and of paraaortic lymph nodes 12.45±6.41. 18F-FDG uptake was detected in a total of 47 lymph node stations in 16 
patients. Mean SUVmax of all lymph nodes were calculated as 8.9±5.83 (range: 2.6-21.9). According to 18F-FDG 
PET/CT findings, disease was upstaged from I to IV in 1 (3%) patient, II to III in 2 (6%) patients, III to IV in 1 (3%) 
patients and I to III in 2 (6%) patients, and down staged from III to I in 1 (3%) patient, respectively. In the patient-based 
analysis, 18F-FDG PET/CT was TP, TN, FP and FN in 14 (%44), 14 (44%), 2 (6%) and 2 (6%) patients, respectively. 
Patients based sensitivity; specificity and accuracy of 18F-FDG PET/CT were calculated as 87%, 87% and 87%, 
respectively. In the lesion-based analysis, 18F-FDG PET/CT was TP, FP, TN and FN in 30, 7, 37 and 5 lymph node 
stations, respectively. Lesion based sensitivity; specificity and accuracy of 18F-FDG PET/CT were calculated as 85%, 
84% and 84%, respectively.  
Conclusion: 18F-FDG PET/CT is a reliable imaging tool with its high sensitivity and specificity in the pelvic and paraaortic 
lymph node staging of uterine cervical cancer. When performed in the preoperative staging it changes disease stage 
about in  of patients. In combination of pelvic MRI, primary staging of primary cervical lesions and also 
pelvic/paraaortic lymph nodes can be done successfully.  
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INTRODUCTION 
Uterine cervical cancer is the second common 
reason for cancer related death in women [1]. Today, 
preoperative staging of disease is mostly done 
clinically. Physical examination, radiograms, 
colonoscopy, colposcopy and intravenous pyelogram 
are routinely utilized diagnostic procedures for 
preoperative evaluation. Although computed 
tomography (CT), magnetic resonance imaging (MRI) 
and 18F-Flourodeoxyglucose (18F-FDG) positron 
emission tomography/computed tomography (PET/CT) 
have been performed for evaluation of local invasion, 
lymph node involvement and distant metastases, they 
have not been included staging protocols [2]. Clinical 
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staging system is a weak parameter to prediction of 
disease prognosis. For this reason, some 
gynecological oncologists believe to importance of 
addition of surgical staging to routine staging protocols. 
In advanced stage cases, knowledge of pelvic and 
paraaortic lymph node involvement in preoperative 
period is very important to application of simultaneous 
and/or neoadjuvant chemo-radio therapy and 
discrimination of radiation therapy field [3-4].  
Surgery is the gold standard for pelvic and 
paraaortic lymph node staging of uterine cervical 
cancer. Preoperative pelvic CT or MRI might be 
insufficient to evaluate of lymph node involvement, in 
especially normal sized lymph nodes. 18F-FDG 
PET/CT is a functional imaging tool that has been 
routinely utilized for preoperative evaluation of lymph 
nodes and distant metastases in several cancer types.  
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In this study, we aimed to evaluate the sensitivity of 
18F-FDG PET/CT in the detection of pelvic and 
paraaortic lymph node metastases of uterine cervical 
cancer in the comparison of surgical staging as gold 
standard. 
MATERIAL AND METHODS 
Patients 
32 female patients (mean age: 56.1±12.6) who 
underwent 18F-FDG PET/CT for preoperative staging 
of uterine cervical cancer between April 2009 and 
October 2013 were included to the study. Ethical 
committee approval was taken from Ankara University 
Medical Faculty Ethics Committee. All the patients had 
been performed trans-vaginal examination and 
diagnosed as uterine cervical cancer before 18F-FDG 
PET/CT.  
18F-FDG PET/CT 
PET/CT images were acquired with GE Discovery 
ST PET/CT scanner (General Electric, Milwaukee, 
Wisconsin, USA). Patients were kept hungry at least 6 
hours before scanning and blood glucose levels were 
checked before FDG injection. Intravenous contrast 
agents were not applied. Whole body 18F-FDG 
PET/CT imaging was performed approximately 1 hour 
after an intravenous injection of 296-370 MBq 18F-
FDG. Patients were rested in a quiet room without 
administrating muscle relaxant during waiting period. 
Images were obtained while patients were in supine 
position, from skull base to mid thighs. CT image was 
obtained from the integrated PET/CT scanner with the 
use of a standardized protocol involving 140 kV, 70 
mA, a tube rotation time of 0.5 s per rotation, a pitch of 
6 and a section thickness of 5 mm. Immediately, after 
the CT part, PET images were acquired for 4 minutes 
per bed position. Emission PET images were 
reconstructed with non-contrast CT data for attenuation 
correction. Patients were allowed to breath normally 
during procedure. 
Image Analysis 
Whole body PET/CT images were interpreted by 
two experienced nuclear medicine physicians by visual 
inspection at least on three planes (transaxial, coronal, 
sagittal). Comparison was made between focus 
increasing uptake and background and blood pool 
activity. After then their anatomic confirmation was 
done with CT images. The criterion for malignancy was 
accepted FDG hypermetabolism at the site of 
pathological changes on CT or marked focal 
hypermetabolism at the physiological uptake sites. 
Maximum standardized uptake value (SUVmax) was 
calculated for all pathologic lesions. 
Data Analysis 
18F-FDG PET/CT findings were compared with 
histopathological examination results. When the 
detected metastatic lesions on 18F-FDG PET/CT were 
confirmed histologically, these lesions were accepted 
as true positive (TP). If recurrence was excluded by 
pathological examinations in patients with positive 
lesions on 18F-PET/CT, findings were classified as 
false positive (FP). Patients with negative scan but 
positive recurrence proved by histological examination 
were accepted as false negative (FN). Negative 18F-
FDG PET/CT scans in patients with no detected 
recurrence in the follow-up period were accepted as 
true negative (TN). 
Statistical Analysis 
TP/FP and TN/FN results were described according 
to criterion mentioned above. Sensitivity and specificity 
were computed using these data. Statistical analyses 
were performed using the SPSS software, version 16 
(SPSS Inc., Chicago, Illinois, USA). Student T test was 
used for comparison of mean values of different 
groups.  
RESULTS  
Patients 
18F-FDG PET/CT was performed to 32 patients 
(mean age; 56.1±12.6; range; 28-77) during the study. 
Before PET/CT, according to cervical pap-smear 
examination, 28 (87%) patients had been diagnosed as 
squamous carcinoma and 4 (13%) patient 
adenocancer. Before PET/CT, clinically, 11 (34%), 7 
(22%), 12 (37%) and 2 (7%) patients had been staged 
as stage I, II, III and IV, respectively (Table 1).  
Pelvic MRI  
Pelvic MRI has been performed to all the patients 
for evaluation of local spread of disease. MRI could 
detect all primary cervical lesions. Additionally, local 
invasion to parametrium, vagina and rectum were seen 
in 5 (15%), 3 (9%) and 1 (3%) patient, respectively. 
MRI showed pelvic lymph node metastases in 15 
(46%) and additionally paraaortic lymph node 
metastasis in 1 (3%) patient, while there was no 
detected lymph node in 17 (%53) patients.  
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Table 1: Descriptive Data of Whole Patient Group 
Patient 
no 
Age 
Preoperative 
Diagnosis 
Pathological 
Subtype 
Clinical 
Stage 
Lymph Nodes 
According to MRI 
Lymph Nodes According to 18F-FDG 
PET/CT (SUVmax) 
1 28 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IVB Bilaterally parailiac  
Left retrocrural (6.5), paraaortic (18.1) 
,paravertebral (21.2), bilaterally 
parailiac (10.9) and presacral (2.9)  
2 77 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IIB Negative Negative 
3 77 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IA 
Left inguinal and left 
obturatory  
Bilaterally inguinal (3.4), 
parailiac  (7.0)   
4 67 
Squamous 
cell carcinoma 
Large Cell 
Keratinized Type 
IIIB Negative Negative 
5 52 
Squamous 
cell carcinoma 
Small Cell Type IIB Negative Right parailiac (4.0) 
6 57 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IIB 
Left parailiac and 
obturatory 
Negative 
7 69 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IIIB Bilaterally parailiac  
Aortocaval (16.9),  
bilaterally parailiac (17.9) 
8 42 
Squamous 
cell carcinoma 
Small Cell Type IIIB 
Paraaortic, paracaval, 
aortocaval and bilaterally 
parailiac  
Bilaterally lumbal (4.0), aortocaval (4.0), 
parailiac  (15.0) and pararectal (2.1) 
9 65 
Squamous 
cell carcinoma 
Large Cell 
Keratinized Type 
IVA 
Pararectal and bilaterally 
parailiac 
Common iliak ve bilateral internal iliak 
(5.5) lenf nodları. 
10 43 
Squamous 
cell carcinoma 
Small Cell Type IIB Negative Negative 
11 57 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IIB Right parailiac Negative 
12 62 
Squamous 
cell carcinoma 
Small Cell Type IIIB Negative Negative 
13 56 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IIB Negative Bilaterally parailiac (5.5) 
14 45 
Squamous 
cell carcinoma 
Small Cell Type IIIB Right parailiac 
Bilaterally parailiac  (15.7),  
pararectal (10.2) 
15 55 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IB Negative Negative 
16 38 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IB Negative Negative 
17 67 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IA Negative Negative 
18 53 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IIIB Bilaterally parailiac  
Paraaortik (11.0), 
 bilaterally parailiac (10.0)  
19 56 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IB Negative Bilaterally parailiac (4.1)  
20 57 
Adeno 
carcinoma 
Villoglandular Type IB Negative Bilaterally parailiac  (13.5)  
21 72 
Squamous 
cell carcinoma 
Large Cell 
Keratinized Type 
IIIB Left parailiac Left parailiac (5.6)  
22 56 
Squamous 
cell carcinoma 
Large Cell 
Keratinized Type 
IIB Negative Negative 
23 28 
Adeno 
carcinoma 
Clear Cell Type IB Negative Negative 
24 52 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IA Negative Negative 
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(Table 1) Contd…. 
Patient 
no 
Age 
Preoperative 
Diagnosis 
Pathological 
Subtype 
Clinical 
Stage 
Lymph Nodes 
According to MRI 
Lymph Nodes According to 18F-FDG 
PET/CT (SUVmax) 
25 42 
Adeno 
carcinoma 
Well-differantiated 
Type 
IIIB Left parailiac Bilaterally parailiac (2.9) 
26 43 
Squamous 
cell carcinoma 
Large Cell 
Keratinized Type 
IB Negative Negative 
27 57 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IB Negative Negative 
28 43 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IIIB Bilaterally parailiac  Negative 
29 39 
Squamous 
cell carcinoma 
Large Cell 
Keratinized Type 
IIIB Bilaterally parailiac  
Right parailiac  (7.5), 
 paraortic (11.5) 
30 39 
Squamous 
cell carcinoma 
Large Cell 
Nonkeratinized Type 
IIIB Bilaterally parailiac  
Bilaterally parailiac (4,1), 
 paraaortic (4,7), sacral (2,6) 
31 39 
Squamous 
cell carcinoma 
Large Cell 
Keratinized Type 
IB Negative Negative 
32 42 
Adeno 
carcinoma 
Clear Cell Type IIIB Right parailiac Left parailiac (8.5) 
 
18F-FDG PET/CT 
18F-FDG uptake was seen in primary cervical 
lesions of all the patients. Mean SUVmax of primary 
cervical lesions was calculated as 13.6±6.6 (range: 6.7-
25). According to histopathological subtypes; SUVmax 
was calculated as 14.38±7.3, 15.2±1.2, 15.36±6,6 and 
6.5±2.8 in large cell keratinized, large cell, small cell 
and adeno carcinoma subtypes, respectively. In the 
analysis according to clinical disease stage, SUVmax 
of primary lesions of patients with stage I, II, III and IV 
disease were found as 18.1±7.2, 10.9±6.5, 12.8±6.7 
and 15.9±1.5, respectively. Difference between 
SUVmax of groups according to either 
histopathological subtype and clinical stage was not 
statistically significance.  
In 16 (50%) patients, 18F-FDG uptake was not seen 
in pelvic and paraaortic lymph nodes. In the remaining 
patients, 18F-FDG uptake was detected in pelvic nodes 
in all the patients (50%) and in paraaortic nodes in 6 
(18%) patients (Table 2). Mean SUVmax of pelvic 
lymph nodes were calculated as 8.4±5.2 and of 
paraaortic lymph nodes 12.45±6.41. 
18F-FDG uptake was detected in a total of 47 lymph 
node stations in 16 patients. Mean SUVmax of all 
lymph nodes were calculated as 8.9±5.83 (range: 2.6-
21.9). According to 18F-FDG PET/CT findings, disease 
was upstaged from I to IV in 1 (3%) patient, II to III in 2 
(6%) patients, III to IV in 1 (3%) patients and I to III in 2 
(6%) patients, and down staged from III to I in 1 (3%) 
patient, respectively.  
Table 2: Lymph Node Status of Patients in Pelvic MRI, 
18F-FDG PET/CT and Histopathology 
Method 
No of Patients  
with Positive  
Lymph Nodes 
No of Patients  
without Positive  
Lymph Nodes 
Pelvic MRI 15 17 
18F-FDG PET/CT 16 16 
Histopathology 14 18 
 
While mean SUVmax of primary cervical lesions of 
patient with positive pelvic lymph nodes was calculated 
as 13.5±6.8, it was as 17.4±5.3 of patients with positive 
paraaortic lymph nodes (p=0.3).  
Gold Standard 
All the patients underwent total abdominal 
hysterectomy, bilateral salpingo-oophorectomy and 
pelvic/paraaortic lymph node dissection. 18F-FDG 
PET/CT findings of these patients were compared with 
histopathological examination reports. In 32 patients, 
total 282 lymph nodes were dissected from 213 lymph 
node stations. 140 out of 213 lymph node stations were 
nonmetastatic histopathologically while 73 metastatic. 
According to gold standard, 10 (31%), 4 (13%), 15 
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(47%) and 3 (9%) patients were staged as stage I, II, III 
and IV. 
In the patient-based analysis, 18F-FDG PET/CT 
was TP, TN, FP and FN in 14 (%44), 14 (44%), 2 (6%) 
and 2 (6%) patients, respectively. Patients based 
sensitivity, specificity and accuracy of 18F-FDG 
PET/CT were calculated as 87%, 87% and 87%, 
respectively (Table 3). 
Table 3: Sensitivity, Specificity and Accuracy of 18F-
FDG PET/CT According to Patient and Lesion 
Based Analysis 
 Sensitivity 
(%) 
Specificity 
(%) 
Accuracy 
(%) 
Patient based 87 87 87 
Lesion based 85 84 84 
 
In the lesion-based analysis, 18F-FDG PET/CT was 
TP, FP, TN and FN in 30, 7, 37 and 5 lymph node 
stations, respectively. Lesion based sensitivity, 
specificity and accuracy of 18F-FDG PET/CT were 
calculated as 85%, 84% and 84%, respectively. While 
mean SUVmax of metastatic and FDG positive lymph 
nodes was computed as 8.96±3.3, it was 4.33±1.05 in 
nonmetastatic and FDG positive lymph nodes (p=0.04). 
DISCUSSION  
FIGO staging system is routinely used for staging of 
cervical cancer. This system based on clinical 
examination and conventional imaging methods [4]. 
While FIGO system is partially more successful in early 
stage of disease, its probability of error has been 
reported as 59%-67% in the advanced stages [4-6]. To 
support this insufficiency, disease was upstaged from I 
to IV in 1 (3%) patient, II to III in 2 (6%) patients, III to 
IV in 1 (3%) patients and I to III in 2 (6%) patients, and 
down staged from III to I in 1 (3%) patient. 
Close relationship between progression free 
survival and age, performance status, tumor diameter 
and pelvic/paraaortic lymph node metastases has been 
reported [7]. Although cross-sectional imaging tools 
have not been included guidelines yet, CT and MRI 
widely have been performed to evaluate morphological 
risk factors such as tumor diameter, depth of stromal 
invasion and presence of lymph node metastasis. 
Although accuracy of CT in the staging of uterine 
cervical cancer has been reported between 58% and 
88%, its sensitivity is low in the evaluation of tumor 
diameter, parametrial invasion and lymph node 
metastasis (44%) [5-6]. Despite the most successful 
method in the assessment of tumor dimension and 
parametrial invasion, sensitivity of MRI in the detection 
of lymph node metastasis is similar to CT [5]. 
As in most solid tumors, 18F-FDG PET/CT has 
been widely utilized to staging, restaging and 
evaluation of treatment response in gynecological 
tumors. Role of 18F-FDG PET/CT is limited in the 
diagnosis of ovarian cancer due to physiological 
ovarian activity. However it may have an additional 
value in the combination of CT or MRI to detect lymph 
node or distant metastases [8]. 
18F-FDG PET/CT has a limited sensitivity in the 
detection of stromal and parametrial invasion of uterine 
and cervical cancer due to its low spatial resolution. 
However, it is very successful in the assessment of 
pelvic and paraaortic lymph node metastases. Grigsby 
et al. showed that 18F-FDG PET/CT is more successful 
than CT in the detection of lymph node metastases and 
presence of FDG uptake in the paraaortic lymph nodes 
is closely related to disease free survival [9]. Yen et al. 
has found that of 18F-FDG PET/CT is more sensitive 
and specific than CT and MRI in their 135 cervical 
cancer patient series [10]. After studies, which show 
high sensitivity and specificity of 18F-FDG PET/CT, 
Centers for Medicare Services has approved its routine 
usage in preoperative staging of cervical cancer 
patients who have negative conventional imaging 
results for extrapelvic metastases [11]. Yıldırım et al. 
have reported sensitivity; specificity and accuracy of 
18F-FDG PET/CT in the detection of paraaortic lymph 
node metastasis are 50%, 83% and 75%, respectively, 
in their 16 patient series who have negative conven- 
tional CT [12]. We have calculated these parameters 
as 87%, 87% and 87%, respectively. However pelvic 
MRI results of all the patients in our study were not 
negative. For this reason sensitivity of our study might 
have been found higher. In our study, FDG uptake has 
seen in pelvic/paraaortic lymph nodes in 3 out of 11 
patients who have negative pelvic MRI. In 2 out of 
these 3 patients, lymph node metastases have con- 
firmed by histopathologically. In our study, while mean 
SUVmax of FDG avid and metastatic lymph nodes was 
calculated as 8.96±3.3, it was 4.33±1.05 in nonmeta- 
static ones. Although some of FDG positive lymph 
nodes have been found nonmetastatic histopathology- 
cally, probability of metastasis is especially higher in 
lymph nodes with intense FDG uptake. For this reason, 
probability of metastasis should be kept in mind in 
lymph nodes with intense FDG uptake even their 
dimensions are not pathological in MRI.  
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Similarly to most solid tumors, differentiation degree 
of primary tumor focus is an important indicator for 
disease free survival in uterine cervical cancer. FDG 
uptake degree is directly related with tumor 
differentiation. In our study, SUVmax of primary 
cervical lesions of clinical stage I, II, II and IV patients 
were calculated as 18.1±7.2, 10.9±6.5, 12.8±6.7 and 
15.9±1.5, respectively. The absence of significant 
difference between stages may be an indicator of 
prognostic insufficiency of FIGO staging system. In this 
patient group, 18F-FDG PET/CT can be a prognostic 
predictor. In support of this hypothesis, mean SUVmax 
of primary cervical lesions of patients who have 
paraaortic lymph node metastases, as an advanced 
disease indicator has been found higher than those 
have not.  
In this study, we could not evaluate the sensitivity of 
18F-FDG PET/CT to reveal stromal or parametrial/ 
vaginal invasions due to limited spatial resolution of 
PET. MRI seems to be the most successful method it 
these purposes. However, addition of 18F-FDG 
PET/CT to pelvic MRI may contribute to more correct 
preoperative staging of cervical cancer by increasing 
accuracy of pelvic/paraaortic lymph node staging. 
Although the disease classically has been staged and 
treated clinically, according to modern approach, 
preoperative staging by pelvic MRI and 18F-FDG 
PET/CT may decrease unnecessary operation rates by 
changing disease stage. In the future possible use of 
18F-FDG PET/MRI may give a chance to get together 
both modalities and make more successful staging in 
same course [13-14]. Generally, although treatment 
choice is radical hysterectomy and pelvic/paraaortic 
lymph node dissection in stage IA-IIA disease, it is 
intracavitary/external radiation therapy in stage IIB-IVA. 
In our series, disease stage of 7 (21%) patients has 
changed by 18F-FDG PET/CT and treatment plan has 
changed in 5 out of them. Similar to our results, 
Yıldırım et al. have reported 25% change in stage in 
their patients [12].  
CONCLUSION 
18F-FDG PET/CT is a reliable imaging tool with its 
high sensitivity and specificity in the pelvic and 
paraaortic lymph node staging of uterine cervical 
cancer. When performed in the preoperative staging it 
changes disease stage about in  of patients. In 
combination of pelvic MRI, primary staging of primary 
cervical lesions and also pelvic/paraaortic lymph nodes 
can be done successfully.  
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